Located in San Diego, California, AnaBios aims to establish the safety and efficacy of novel compounds through its advanced, human-focused translational technologies.

AnaBios’ human tissue-based methods provide a very powerful strategy that combines the benefit of in vivo measurements (in animals) with the ability to generate human data (ex vivo) to overcome the challenges of cross-species translation.

AnaBios’s objective is to generate human ex vivo data for the biopharmaceutical industry:

  • Target identification, MOA investigation, compound profiling on human tissue
  • Tests in hDRG for PAIN drug discovery
  • Neurotoxicity test in hDRG
  • Safety pharmacology assays with human cardiomyocytes and tissue preparations

ANABIOS NEUROSCIENCE EXPERTISE

AnaBios offers early human insights into the drug development process and is redefining “First-in-Human” studies. Leveraging extensive knowledge of human tissue procurement and strategic utilization, AnaBios provides the unprecedented opportunity to de-risk drug development programs by assessing the safety and efficacy of drugs directly in human tissues and cells at the preclinical stage.

Human tissue-based assays

Human dorsal root ganglia (hDRG) cultured neurons from Normal and Chronic Pain Donors

Techniques (Assays in isolated adult hDRG neurons):

–        Electrophysiology – current clamp

–        Calcium imaging with electrical field stimulation

Case study

Clone Cardiac Ion Channel Data

Learn more

Case Study

Predicting Heart Rate Effects on Ex Vivo Human Sa Node

Learn more

AnaBios Experts

Andre GHETTI, PhD
CEO
ANABIOS
Paul E. MILLER, PhD
CBO
ANABIOS
Najah ABI-GERGES, PhD
VP of R&D
ANABIOS

More about AnaBios